Category Archives: Genetics

College of Medicine graduate student launches genetics research start-up – Penn State News

HERSHEY, Pa. Olivier Noel is only 28 years old, but hes already changing the face of genetics research.

The Haitian native is in his sixth year of Penn State College of MedicinesMD/PhD Medical Scientist Training Programand was recently recognized by Forbes as one of the countrys brightest young entrepreneurs on its30 Under 30 list in the science industry. Hes the founder of DNAsimple, a startup aimed at accelerating genetics research by connecting DNA donors with research scientists. The company provides scientists with access to critically important samples, significantly speeding up the pace for genetics research.

People dont realize it can take years to get samples, but really only a month to get an assignment done which is a little bit ridiculous, Noel said. Its a problem for geneticists across the board. You can have a million dollars to do a study, but waste three years trying to get samples.

Noel explained a light bulb went off when he attended a genetics conference at the recommendation of Dr. Roger L. Ladda, whom he had been shadowing with the intent of focusing his residency on genetics.

The keynote speaker at the conference was talking about how he was studying a disease not really prevalent in the Western world, and the way they were able to get a DNA sample to validate was through Facebook. The joke at the time was that Facebook is the new way of doing genetics. I realized, wow, that worked well for one case but thats not the way science should get done, Noel said.

Noels big break was when the company was accepted into the Y Combinator program, which includes such notable alumni as Dropbox, Airbnb and Reddit. DNAsimple was one of 32 companies accepted from more than 6,500 applicants worldwide, he said. But he credits his doctoral advisors former Penn State faculty member Dr. Glenn S. Gerhard and Penn State College of Medicine Chair of Biochemistry and Molecular BiologyJames Broach for teaching him about genetics and exposing him to the Penn State Institute for Personalized Medicine.

Learn more about Noel and his work in this Penn State Medicine article.

Last Updated February 13, 2017

See the original post:
College of Medicine graduate student launches genetics research start-up - Penn State News

Cocaine addiction a matter of genetics, UBC researchers say – Calgary Herald

Scientists at the University of B.C.have built a better mouse one that is indifferent to cocaine.

Unlike normal mice, the genetically engineered rodents did not show addictive behaviour even after repeated injections of the narcotic over days, suggesting that habitual drug use in humans may be a matter of genetics.

While the finding is unlikely to yield a pill that cures addiction anytime soon, it could lead to a test that identifies who is at greatest risk of addiction and enable people to act on that knowledge, saidShernaz Bamji, the lead author of a study published today by the journal Nature Neuroscience.

The finding provides a biochemical model for addiction based onprevious work at Johns Hopkins University in Baltimore, Md., that found people with genetic mutations associated with a class of proteins in the brain called cadherins are more prone to substance abuse.

Cadherin helps bind cells together and play a role inwhich brain circuits are strengthened during learning even learning that certain drugs deliver pleasure.

Although Bamji had theorized that higher levels of cadherin would lead to more addictive behaviour, the opposite turned out to be true.

To better understand its role, the researchers engineered mice to produce excessive cadherin proteins in their brains.

Bamji and her collaboratorsinjected normal and genetically engineered mice with cocaine and placed them in a distinctly decorated room within a multi-room cage. On alternating days the mice were placed in the other room and injected with saline, said co-author Andrea Globa.

After six days of alternating treatments, the mice wereallowed to move freely to any of the rooms in the cage.

The normal mice greatly preferred the cocaine-associated room, but the high-cadherin mice didnt much care for it, suggesting that the presence of extra cadherin had somehow interfered with the learned response to cocaine.

Normal mice always gravitate to the chamber where they received the drug, looking for that high, but the mutant mice didnt, said Bamji.

The answer to the mysterious result was found inside the membrane of brain cellsthemselves, where cadherin interfered with the ability of a specialized proteinreceptor to functionat the synapse, the point at which neurons communicatewith each other chemically toform memories.

Unable to strengthen the connection between synapses, the brains learning circuitry couldntretaincocaines pleasurable memory.

Addiction is a form of learning in the reward circuits of the brain, she said. Where you dont get synapse strengthening, you arent getting learning and you arent getting addiction.

However, because many synapsesin the brain use the same strategy to learn, a magic bullet or pill for addiction is a long way off.

Simply increasing cadherin would likely prevent (addicts)from learning anything new, she said. Thats not a very good trade-off.

Future research might uncover a protein or enzyme in the brainmore specific to addiction that functions only in the reward circuitry of the brain, which could be a target for medication.

rshore@postmedia.com

CLICK HERE to report a typo.

Is there more to this story? Wed like to hear from you about this or any other stories you think we should know about. Email vantips@postmedia.com.

View post:
Cocaine addiction a matter of genetics, UBC researchers say - Calgary Herald

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics – TheStreet.com

Shares of Sage Therapeutics ( SAGE) were up 8.6% ahead of the opening bell on Monday, trading at $51.50. The Cambridge, Mass. company unveiled encouraging top-line results from part A of its phase 2 study of SAGE-217 for the treatment of major depressive disorder. "Understanding the caveats associated with open-label data, we are highly encouraged by the strong signal we achieved in this study, which met our internal criteria for achieving a positive signal and thus supported our plan to proceed to the double-blind, placebo-controlled part of the Phase 2 trial," said Sage CEO Jeff Jonas in a statement.

Meanwhile, Immunomedics ( IMMU) shares rose 8% to $5.65 after finishing Friday's trading session at $5.23, up 21.6%. The Morris Plains, N.J. company on Friday announced a global licensing agreement with Seattle Genetics ( SGEN) for sacituzumab govitecan, Immunomedics' solid tumor therapy candidate.

Other biotech stock movers on Monday morning include molecular diagnostic company Myriad Genetics ( MYGN) , whose shares were up 6.2%, to $16.98.

Follow this link:
Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics - TheStreet.com

Seattle Genetics Earnings: Waiting on ECHELON – Motley Fool

2017 is looking like a transition year for the biotech.

Seattle Genetics (NASDAQ:SGEN) released fourth-quarter earnings on Thursday and gave investors a taste of what's to come later this year. With modest growth for Adcetris, its only drug on the market, investors should be focused on Seattle Genetics' pipeline and clinical trials that could further expand sales of Adcetris.

Metric

Q4 2016

Q4 2015

Year-Over-Year Change

Revenue

$105 million

$93 million

12.6%

Income from operations

($55.8 million)

($25.1 million)

N/A

Earnings per share

($0.39)

($0.18)

N/A

Data source: Seattle Genetics.

Image source: Getty Images.

Clay Siegall, Seattle Genetics' president and CEO, asked investors to look past 2017 guidance and see the bigger picture: "What is really important with Adcetris is not the sales we have now. What's really important is going toward the big items of [ECHELON-1] and [ECHELON-2], and you can even include ALCANZA in there."

On the delay of submitting the application for CTCL patients, Siegall didn't even want to call it that. "To me it's not a delay. To me it's taking advantage of an opportunity," he said. "I think we have a really good opportunity to end up with a bigger market if we can get a bigger label."

Management guided for Adcetris sales of $280 million to $300 million this year, which is 5.3% to 12.9% higher than last year's sales. Royalty revenue is expected to be in the $50 million to $55 million range, down from the $67.5 million in 2016, but last year included a $20 million milestone payment.

The difference between the bottom and top of guidance likely has to do with how many doctors prescribe Adcetris for CTCL off-label ahead of the FDA approval. But capturing those patients now versus next year isn't particularly important for Seattle Genetics' long-term value.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Read the original:
Seattle Genetics Earnings: Waiting on ECHELON - Motley Fool

miRagen Therapeutics (MGEN) Completes Merger with Signal Genetics (SGNL) – StreetInsider.com

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced the completion of its merger with Signal Genetics, Inc. (Nasdaq: SGNL) , effective February 13, 2017. Concurrent with the closing of the merger, miRagen received gross proceeds of $40.7 million in new equity investment from a combination of current and new miRagen investors, including Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (a venture fund of Merck, known as MSD outside the United States and Canada), Remeditex Ventures, and others. Together with pre-merger cash on miRagens balance sheet, the combined company has approximately $60 million in cash and short-term investments.

Upon completion of the merger today, Signal was renamed Miragen Therapeutics, Inc. The combined company will commence trading on The NASDAQ Capital Market under the symbol MGEN on February 14, 2017.

The completion of this merger marks a significant step forward for miRagen, our investors and potentially thousands of patients awaiting a therapeutic option for their conditions, said miRagen President and CEO William S. Marshall, Ph.D. The equity investment aligns the companys cash resources with our plan to advance the first two clinical programs into additional trials and to develop a compelling pipeline of targeted product candidates, each focused on patient populations with few clinical options. We believe these transactions will help us create a more focused and well financed organization as we build an exciting enterprise, an innovative culture and value for current and future stockholders.

Following the completion of the financing and merger, the combined company has approximately 21.3 million shares of common stock outstanding.

miRagens stockholders, including those who invested in the concurrent financing, received common stock, representing approximately 95.2% of the outstanding shares. Signals stockholders retained approximately 4.8% of the combined company.

The combined company will operate under the leadership of Dr. Marshall, and the board of directors of the combined company is comprised of seven members: Bruce Booth, John Creecy, Thomas Hughes, Kevin Koch, Kyle Lefkoff, Joseph Turner and Dr. Marshall.

Wedbush PacGrow acted as placement agent for miRagen in the financing.

Here is the original post:
miRagen Therapeutics (MGEN) Completes Merger with Signal Genetics (SGNL) - StreetInsider.com

Genetics of height: It may be too complex for scientists to crack the code – Genetic Literacy Project

[W]hen the human genome was sequenced, scientists like [Joel Hirschhorn, a geneticist at Boston Childrens Hospital and the Broad Institute] thought they could plumb that data to track all the height genes.

That effort started slowly. But now, Hirschhorn says, For height there are about 700 variants known to affect height, each of them usually with a pretty small effect on height, usually like a millimeter or less.

Even so, the traits [Hirschhorn] found only explain about a quarter of the inherited height factors. And, frustratingly, for most of those variants scientists have no idea what they actually do.

Hirschhorn and his colleagues are expanding their already massive study of 700,000 subjects. That approach has drawn skepticism from some scientists, who think its a waste of effort.

David Goldstein, a professor of genetics at Columbia University, says an expanded effort could ultimately implicate every gene in existence, and that hardly helps scientists narrow down the biological factors that contribute to height.

Its likely scientists will never be able to figure out what these hundreds of common variants do to influence height, Goldstein says. Instead, a much better strategy is [to look] for rare variants that pack a big punch.

[The study can be found here.]

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Genetics of Height is Way Complex, It Turns Out

See the article here:
Genetics of height: It may be too complex for scientists to crack the code - Genetic Literacy Project

Will Seattle Genetics’ Deal With Immunomedics Get Scuttled? – Madison.com

Last week, Seattle Genetics (NASDAQ: SGEN) announced an agreement to licenseImmunomedics'(NASDAQ: IMMU) IMMU-132, a cancer drug that's already completed midstage phase 2 trials.

The deal could be a big win for Seattle Genetics, but it doesn't have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC -- the beneficial owner of 9.9% of Immunomedics shares -- said Immunomedics' board of directors is "giving away its crown jewel."

IMAGE SOURCE: GETTY IMAGES.

If the deal closes, Seattle Genetics will take over development of IMMU-132, an anti-TROP-2 antibody that can target multiple tumor types. Breast cancer, lung cancer, and colorectal cancers all overexpress the TROP-2 protein and therefore could conceivably be treated by IMMU-132.

In phase 2 trials of IMMU-132 in triple negative breast cancer, there was a 29% overall objective response rate in heavily pretreated patients. Historically, the duration of response in fifth-line triple negative breast cancer patients is measured in months, but IMMU-132 delivered a 10-month duration of response and a median overall survival rate of over 18 months.

About 15% of breast cancer patients are triple negative, and patients with this type of breast cancer have a poor prognosis. According to the National Cancer Institute, 246,660 new cases of breast cancer are diagnosed annually, causing 40,450 deaths every year.

There's a big need for new treatments, and that hasSeattle Genetics thinking IMMU-132 could qualify for an accelerated FDA approval. If so, then IMMU-132 will become Seattle Genetics' second commercial-stage drug. Management didn't offer up a timeline for filing a new drug application with the FDA; however, it did say it's going to evaluate its options and update investors on a future conference call.Last fall, Immunomedics told investors it hoped to file for FDA accelerated approval in the middle of 2017.

Seattle Genetics will pay Immunomedics $250 million in cash up front, plus an additional $50 million payment related to ex-U.S., Canada, and EU rights. If it wins an FDA green light, Immunomedics has an option to co-market IMMU-132 in America. Otherwise,Seattle Genetics will pay Immunomedics a tiered double-digit royalty that's based on sales.

Seattle Genetics also agreed to pay Immunomedics up to $1.7 billion in regulatory and sales milestone payments on IMMU-132, and Seattle Genetics agreed to let Immunomedics continue negotiating with other companies on rights to IMMU-132 until Feb. 19. If a competing offer is made, Seattle Genetics can match it. If Immunomedics selects a competing offer, then it will pay Seattle Genetics a breakup fee.

Separately, Seattle Genetics acquired 3 million shares of Immunomedics at $4.90 per share that aren't tied to the closing of this deal. Seattle Genetics also secured three-year warrants that allow it to acquirean additional 8,655,804 shares at $4.90 each.

Seattle Genetics already markets the lymphoma drug Adcetris, which is FDA approved for treating Hodgkin lymphoma patientswhose disease has progressed after autologous stem-cell transplant or after two prior chemotherapy treatments, if ineligible for transplant.Adcetris is also used to treat patients with systemic anaplastic large-cell lymphomawhose disease has progressed after one prior chemotherapy treatment. A trial evaluatingAdcetris as a front-line Hodgkin lymphoma therapy is anticipated to read out data this year.

With$265.8 millionin sales last year, Adcetris is no slouch, but IMMU-132 has the potential to haul in far more in revenue than that. Immunomedics commissioned an independent analysis of IMMU-132's market potential last year, and that study estimates that IMMU-132 could generate annual sales of $3 billion in 2025, if it gets approved for use in triple negative breast cancer,urothelial cancer, and lung cancer.

That's a big opportunity, but there's no guarantee that IMMU-132 will get an early OK from the FDA, and if it doesn't, then Seattle Genetics will have to conduct a confirmatory phase 3 study. While midstage trial results were solid, investors should remember that, historically, 30% to 40% of drugs that advance into phase 3 trials fail.

Of course, for Seattle Genetics to benefit from IMMU-132 at all, this deal has to close, and based on venBio's comments, that might not be a given. Immunomedics is engaged in a proxy fight with venBio, and in its statement onFriday,venBio's Behzad Aghazadeh said, "Immunomedics' announcement of a deal with Seattle Genetics is a blatant and shameful maneuver by the current board and management to manipulate the outcome of the upcoming annual meeting and entrench themselves at the expense of stockholders' best interests, and venBio is exploring all options to hold them accountable."

10 stocks we like better than Seattle Genetics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Seattle Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

*Stock Advisor returns as of February 6, 2017

Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Read the original post:
Will Seattle Genetics' Deal With Immunomedics Get Scuttled? - Madison.com

Genetics of both virus and patient work together to influence the … – Medical Xpress

February 9, 2017 HIV, the AIDS virus (yellow), are infecting a human cell. Credit: ZEISS Microscopy / Flickr

Viral and human genetics together account for about one third of the differences in disease progression rates seen among people infected with the human immunodeficiency virus (HIV), according to new research published in PLOS Computational Biology. The findings suggest that patient genetics influences disease progression by triggering mutations in the HIV viral genome.

People with HIV experience different rates of disease progression. HIV progresses faster in people with a higher viral loadthe amount of genetic material from the HIV virus found in an infected person's blood.

Previous research has shown that an infected person's genetics and the genetics of their particular HIV strain both influence viral load. Istvn Bartha of cole Polytechnique Fdrale de Lausanne, Switzerland, and colleagues are now the first scientists to investigate the relative impacts of human and viral genetics on viral load within the same group of patients.

The researchers collected patient and viral genetic data from 541 people with HIV. They used a computational modeling method known as linear mixed modeling to determine how human and viral genetics might explain differences in viral load between the patients.

They found that genetic differences between HIV strains explain 29 percent of differences in viral load between patients, while human genetic variation explains 8.4 percent. Together, they explain just 30 percent of viral load variation, indicating that patient genetics exert most of its influence by inducing genetic mutations in the HIV virus as it multiplies inside the patient.

"Our paper demonstrates that the genetic make-up of both the patient and the infecting virus contribute to the clinical course of HIV infection," says study director Jacques Fellay.

Further research with a larger group of patients is needed to confirm and refine the findings. Nonetheless, "combining host and pathogen data gave us new insight into the genetic determinants of HIV control," Fellay says. "A similar strategy could be used to better understand other chronic infectious diseases."

Explore further: New antiretroviral drugs decrease chances of HIV sexual transmission

More information: Bartha I, McLaren PJ, Brumme C, Harrigan R, Telenti A, Fellay J (2017) Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control. PLoS Comput Biol 13(2): e1005339. DOI: 10.1371/journal.pcbi.1005339

More than 2 million people were infected by human immunodeficiency virus (HIV) in 2015 via sexual transmission. Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Daniel Podzamczer, have evaluated ...

Scientists have found potential evidence of Ebola virus replication in the lungs of a person recovering from infection, according to new research published in PLOS Pathogens. The findings could aid research into new treatment ...

(Medical Xpress)A large international team of researchers has conducted a study that has shed some light on the role genetic variation plays on HIV viral load levels in patients infected with the virus. In their paper ...

Individuals infected with HIV exhibit both severe immune deficiency and aberrant inflammation, resulting in susceptibility to secondary infection as the disease progresses. HIV-associated deficiencies in adaptive immune responses ...

Scientists have identified a 'molecular barcode' in the blood of patients with Ebola virus disease that can predict whether they are likely to survive or die from the viral infection.

(HealthDay)In patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), low HCV viral load predicts better long-term surgical outcomes, regardless of the serologic eradication of HCV, according to research ...

Viral and human genetics together account for about one third of the differences in disease progression rates seen among people infected with the human immunodeficiency virus (HIV), according to new research published in ...

A new biologic agentthe most potent of its kind so faris showing early promise as part of a potential new strategy for treating HIV. The drug, known as 10-1074, may also offer a new way to prevent viral infection in ...

A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far separately-used AIDS treatments are ...

When someone is HIV-positive and takes antiretroviral drugs, the virus persists in a reservoir of infected cells. Those cells hide out in germinal centers, specialized areas of lymph nodes, which most "killer" antiviral T ...

(Medical Xpress)A large international team of researchers has created what they are describing as the most powerful HIV-attacking antibody ever made. In their paper published in the journal Science Immunology, the team ...

A drug developed at the University of Rochester Medical Center extends the effectiveness of multiple HIV therapies by unleashing a cell's own protective machinery on the virus. The finding, published today in the Journal ...

Adjust slider to filter visible comments by rank

Display comments: newest first

I never taught Dr ILLUOBE who could ever get my HIV-AIDS cured with his herbal product.despite all these happening to me.I always spend a lot to buy a HIV drugs from hospital and taking some several medications but no relieve until one day i was just browsing on the internet when i came across a great post of ! Williams Fran-ca who truly said that she was been diagnose with HIV and was healed that very week through the help of these great powerful healing spell doctor. sometime i really wonder why people called him Dr ILLUOBE,i never knew it was all because of the great and perfect work that he has been doing that is causing all this. so i quickly contacted him and he ask me some few questions and he said a thing i will never forget that anyone who contacted him is always getting his or her healing in just 6 hours after doing all he ask you so i was amazed all the time i heard that from him ,so i did all things only to see that at the very day which he said i will be healed all the st

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:
Genetics of both virus and patient work together to influence the ... - Medical Xpress

Company Spotlight: Signal Genetics – RTT News

Shares of molecular genetics diagnostic company Signal Genetics Inc. (SGNL) have gained more than 60% in the last five trading days.

To find biotech stocks with more profit potential, please visit RTTNews' Emerging Biostocks page.

Last October, Signal Genetics and privately-held Miragen Therapeutics Inc. agreed to merge to create a clinical-stage, NASDAQ-listed, Biopharmaceutical Company developing proprietary micro RNA-targeted therapeutics.

As part of the agreement, stockholders of Miragen will become holders of approximately 96% of Signal's outstanding common stock on a fully-diluted basis.

The combined company will be named Miragen Therapeutics Inc., and will trade on the NASDAQ Capital Market under ticker symbol "MGEN." The proposed merger is expected to close in the first quarter of 2017.

Miragen has two product candidates in phase I testing - MRG-106 for patients suffering from cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides (MF) sub-type, and MRG-201, an anti-fibrosis product candidate that is being tested in healthy volunteers.

On November 29, 2016, Signal agreed to sell all of its intellectual property assets relating to MyPRS test to Quest Diagnostics Investments LLC for $825,000, plus an additional $100,000 if Quest exercised the option to require Signal to operate Signal's lab beyond December 31, 2016 (but not later than January 14, 2017).

Myeloma Prognostic Risk Signature, or MyPRS, test analyses the activity of genes to predict whether an individual is at high risk or low risk for early relapse. Knowing the risk of relapse helps to predict patient outcome.

A special meeting of Signal Genetics' stockholders to vote on matters related to the proposed merger with Miragen Therapeutics Inc. and the sale of Signal's MyPRS intellectual property assets is to be held at 9:00 a.m., local time, on February 10, 2017.

In order to regain compliance with the minimum bid price requirement of the NASDAQ Capital Market, a 1-for-15 reverse stock split of common stock was implemented by Signal Genetics on November 7, 2016.

SGNL has traded in a range of $0.12 to $17.74 over the last 52 weeks. The stock closed Thursday's trading at $14.50, up 7.65%. In after-hours, the stock gained another 3.38% to $14.99.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Read more here:
Company Spotlight: Signal Genetics - RTT News

The tragic story of Soviet genetics shows the folly of political meddling in science – Cosmos

A few years ago, one of us (Ian) was lucky enough to be invited to visit the N.I. Vavilov Institute of Plant Industry in St Petersburg, Russia. Every plant breeder or geneticist knows of Nikolai Vavilov and his ceaseless energy in collecting important food crop varieties from all over the globe, and his application of genetics to plant improvement.

Vavilov championed the idea that there were Centres of Origin (or Diversity) for all plant species, and that the greatest variation was to be found in the place where the species evolved: wheat from the Middle East; coffee from Ethiopia; maize from Central America, and so on.

Hence the Centres of Origin (commonly known as the Vavilov Centres) are where you should start looking to find genotypes the set of genes responsible for a particular trait with disease resistance, stress tolerance or any other trait you are looking for. This notion applies to any species, which is why you can find more human genetic variation in some African countries than in the rest of the world combined.

By the late 1920s, as director of the Lenin All-Union Academy of Agricultural Sciences, Vavilov soon amassed the largest seed collection on the planet. He worked hard, he enjoyed himself, and drove other eager young scientists to work just as hard to make more food for the people of the Soviet Union.

However, things did not go well for Vavilov politically. How did this visionary geneticist, who aimed to find the means for food security, end up starving to death in a Soviet gulag in 1943?

Enter the villain, Trofim Lysenko, ironically a protg of Vavilovs. The notorious Vavilov-Lysenko antagonism became one of the saddest textbook examples of a futile effort to resolve scientific debate using a political approach.

Lysenkos name leapt from the pages of history and into the news when Australias Chief Scientist, Alan Finkel, mentioned him during a speech at a meeting of chief scientists in Canberra this week.

Finkel was harking back to Lysenko in response to news that US President Donald Trump had acted in January to censor scientific data regarding climate change from the Environmental Protection Agency. Lysenkos story reminds us of the dangers of political interference in science, said Finkel:

Lysenko believed that successive generations of crops could be improved by exposing them to the right environment, and so too could successive generations of Soviet citizens be improved by exposing them to the right ideology.

So while Western scientists embraced evolution and genetics, Russian scientists who thought the same were sent to the gulag. Western crops flourished. Russian crops failed.

The emerging ideology of Lysenkoism was effectively a jumble of pseudoscience, based predominantly on his rejection of Mendelian genetics and everything else that underpinned Vavilovs science. He was a product of his time and political situation in the young USSR.

In reality, Lysenko was what we might today call a crackpot. Among other things, he denied the existence of DNA and genes, he claimed that plants selected their mates, and argued that they could acquire characteristics during their lifetime and pass them on. He also espoused the theory that some plants choose to sacrifice themselves for the good of the remaining plants another notion that runs against the grain of evolutionary understanding.

Pravda formerly the official newspaper of the Soviet Communist Party celebrated him for finding a way to fertilise crops without applying anything to the field.

None of this could be backed up by solid evidence. His experiments were not repeatable, nor could his theories claim overwhelming consensus among other scientists. But Lysenko had the ear of the one man who counted most in the USSR: Joseph Stalin.

The Lysenko vs Vavilov/Mendel/Darwin argument came to a head in 1936 at the Conference of the Lenin Academy when Lysenko presented his -ism.

In the face of scientific opinion, and the overwhelming majority of his peers, Pravda declared Lysenko the winner of the argument. By 1939, after quite a few scientists had been imprisoned, shot or disappeared, including the director of the Lenin Institute, there was a vacancy to be filled. And the most powerful man in the country filled it with Trofim Lysenko. Lysenko was now Vavilovs boss.

Within a year, Vavilov was captured on one of his collection missions and interrogated for 11 months. He was accused of being a spy, having travelled to England and the United States, and been a regular correspondent with many geneticists outside the Soviet Union.

It did not help his cause that he came from a family of business people, whereas Lysenko was of peasant stock and a Soviet ideologue. Vavilov was sent to a gulag where, tragically, he died in 1943.

Meanwhile, his collection in Leningrad was in the middle of a 900-day siege. It only survived thanks to the sacrifice of his team who formed a militia to prevent the starving population (and rats) from eating the collection of more than 250,000 types of seeds, fruits and roots even growing the potatoes in their stock near the front to ensure the tubers did not die before losing their viability.

In 1948, the Lenin Academy announced that Lysenkoism should be taught as the only correct theory, and that continued until the mid-1960s.

Thankfully, in the post-Stalin era, Lysenko was slowly sidelined along with his theory. Today it is Vavilov who is considered a Soviet hero.

In 1958, the Academy of Science began awarding a medal in his honour. The leading Russian plant science institute is named in his honour, as is the Saratov State Vavilov Agrarian University. In addition, an asteroid, a crater on the Moon and two glaciers bear his name.

Since 1993, Bioversity International has awarded Vavilov Frankel (after Australian scientist Otto Frankel) fellowships to young scientists from developing countries to perform innovative research on plant genetic resources.

Meanwhile, research here in Australia, led by ARC Discovery Early Career Fellow Lee Hickey, we are continuing to find new genetic diversity for disease resistance in the Vavilov wheat collection.

In the post-Soviet era, students of genetics and agriculture in Russia are taught of the terrible outcomes of the applications of Lysenkoism to Soviet life and agricultural productivity.

Lysenkoism is a sad and terrible footnote in agricultural research, more important as a sadly misused -ism in the hands of powerful people who opt for ideology over fact. Its also a timely reminder of the dangers of political meddling in science.

Ian Godwin, Professor in Plant Molecular Genetics, The University of Queensland and Yuri Trusov, Plant molecular biologist, The University of Queensland

This article was originally published on The Conversation and republished here with permission. Read the original article.

More from Cosmos Conversation

See more here:
The tragic story of Soviet genetics shows the folly of political meddling in science - Cosmos